1.BODY MASS INDEX AND BREAST CANCER PROGNOSIS
Tianfeng WANG ; Yangsheng YU ; Benyao LIN
China Oncology 1999;0(Z1):-
2?cm)tumors,with or without positive lymph nodes,with or without tamoxifen treatment,and of different ER/PR status of their primary tumors were compared among the three BMI groups.RESULTS PR positivity was positively related to BMI( P
2.The clinical and pathological study in moulding operation about breast cancer
Jingtai ZHANG ; Benyao LIN ; Ailian ZHAO ; Al ET
China Oncology 2001;0(02):-
Purpose:We shall provide the clinical and pathological bases in breast cancer operation in which the nipple and ring reserved.Methods:We combine clinical and pathological material , analyses the result of the nipple and ring that cut off wholly and the sample cut down in slice continuously. We analysis the DNA polyploid of carcinoma tissue in FCM technology . Sinonimously , we measure the PCNA expression in immunohistochemistory. We reserve the breast of patients that suffer from breast cancer and further discuss the possibility and safely .The study will provide practice evidence for breast cancer patients who would perform operation. Results:We measure the linear distance from edge of tumor to ring that are 19.6mm. and The patient suffer from breast cacinoma in stage and tumor bed under nipple and ring could not perform operation that reserved nipple and ring.Conclusions:If we stringent control the standard in reservation of breast, The patients suffering from breast cancer will be safely more and more.
3.Association between MDM2 SNP309 Polymorphism and Breast Cancer Risk in Chinese Women
Can WU ; Ye XU ; Tao OUYANG ; Jinfeng LI ; Fianfeng WANG ; Zhaoqing FAN ; Tie FAN ; Benyao LIN ; Yuntao XIE
Chinese Journal of Clinical Oncology 2010;37(3):131-133
Objective: To investigate the correlation of MDM2 SNP309 polymorphism with breast cancer risk in Chinese women. Methods: The polymorphism of MDM2 SNP309 was detected by PCR-restriction frag-ment length polymorphisms assay (PCR-RFLP) in 698 women with primary breast cancer and 525 healthy controls. Results: Compared with the T/T genotype, the G allele (T/G or G/G) was not associated with an in-creased risk of breast cancer in the entire population studied (T/G, adjusted OR=1.2, 95% CI: 0.8-1.6, P=0.30; G/G, adjusted OR=1.0, 95% CI: 0.7 ~ 1.5, P=0.88). Among postmenopausal women, the G allele (T/G or G/G) was significantly associated with an increased risk of breast cancer (T/G, adjusted OR=1.8, 95% CI:1.2~3.0, P=0.011; G/G, adjusted OR=1.9, 95% CI: 1.2~3.3, P=0.014). But this association was not ob-served among premenopausal women. Conclusion: MDM2 SNP309 heterozygous T/G genotype and homozy-gous mutant GIG genotype increase breast cancer risk in postmenopausal Chinese women.
4.Comparison of other cancers in Chinese han women with familial and sporadic breast cancer
Jing LIU ; Juan ZHANG ; Tao OUYANG ; Jinfeng LI ; Tianfeng WANG ; Zhaoqing FAN ; Tie FAN ; Benyao LIN ; Yuntao XIE
International Journal of Surgery 2012;39(7):461-464
ObjectiveTo investigate the family history of other cancers in Chinese han women with familial or sporadic breast cancer.Methodswe analyzed the clinical date of 4 847 primary breast cancer patients cancer patients were treated at the Breast Cancer,Peking University Cancer Hospital between October 2003 and February 2011,among them,465 were familial and4 382 were sporadic breast cancer patients.The differences of family history of cancers other than breast or ovarian cancers were compared between the patients with familial breast cancer and sporadic breast cancer.Results The proportion of cancers other than breast or ovarian cancers in familial breast cancer patients was significantly higher than that in sporadic breast cancer patients(29.7% vs 20.8%,odds ratio 1.61,P< 0.001).Furthermore,the proportion in pancreatic cancer,prostate cancer,and renal cancer in familial breast cancer patients was significantly higher than that of sporadic breast cancer patients ( pancreatic cancer:2.2% vs 0.8%,P =0.002 ; prostate cancer:1.5% vs 0.3%,P < 0.001 ; renal cancer:1.1% vs 0.4%,P =0.03,respectively).And the relative risks of pancreatic cancer,prostate cancer,and renal cancer in the familial breast cancer patients were 2.90-fold,6.07-fold,and 2.97-fold higher than that of sporadic breast cancerpatients,respectively.ConclusionsOur results suggest that the relative risk of cancer other than breast or ovarian in familial breast cancer patients is significantly higher than that in sporadic breast cancer patients,especially pancreatic cancer,prostate cancer,and renal cancer.
5.Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients
Yan WEI ; Jinfeng LI ; Tianfeng WANG ; Yuntao XIE ; Zhaoqing FAN ; Tie FAN ; Aiping LU ; Tao OUYANG ; Benyao LIN
Journal of Peking University(Health Sciences) 2003;0(05):-
Objective:To investigate the associations between the hormone receptors,Ki67 expression and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients.Methods:One hundred sixty-eight primary breast cancer patients received anthracycline-based neoadjuvant chemotherapy.The expression of estrogen receptor(ER),progesterone receptor(PR),and Ki67 were determined by immunohistochemistry assay in core-needle biopsy specimens prior to the chemotherapy,and pathologic response was assessed by Miller & Payne grade(G1 to G5).Results:40%(67/168)of the patients had a good pathologic response,defined as complete pathologic response(pCR or G5)and minimal residual disease(G4).Among the patients,20%(33/168)had a complete pathologic response(G5).ER or PR status was significantly associated with pathological response.Patients with PR-negative tumors had a higher pathological response rate or pCR than those with PR-positive tumors(17/67 vs 45/90,P=0.002;6/67 vs 25/90,P=0.003,respectively),whereas patients with ER-negative tumors had a higher pathological response rate than those with ER-positive tumors.Moreover,Patients with both ER-and PR-negative tumors exhibited a remarkable pathological response as compared with those with any single factor(36/17 vs 26/86,P=0.009).No association between Ki67 expression and pathological was found in this cohort of patients.There was a linear correlation between the expression of Ki-67,ER or PR status and pathologic response.Conclusion:There is a significant association between the hormone receptors and pathological response to neoadjvant anthracycline-based chemotherapy in breast cancer patients,and patients with PR-negative tumors are more likely to respond to chemotherapy.
6.Sentinel lymph node biopsy for breast cancer patients after neoadjuvant chemotherapy
Jinfeng LI ; Tao OUYANG ; Xuejuan WANG ; Tianfeng WANG ; Yuntao XIE ; Zhaoqing FAN ; Baohe LIN ; Zhi YANG ; Benyao UN
Chinese Journal of General Surgery 2000;0(12):-
Objective To evaluate the clinical significance of sentinel lymph nodes biopsy (SLNB) in breast cancer patients after neoadjuvant chemotherapy. Methods SLNB was performed in sixty primary breast cancer patients after neoadjuvant chemotherapy using a combination of 99mTc- Rituximab and patent blue. SLN was examined by routine pathologic examination and immunohistochemistry. Routine axillary lymph node resection was performed after SLNB. Results The successful rate of SLNB was 95% (57/60). Twenty-three cases of SLN (40% ) were metastasis positive, including 18 positive cases detected by HE staining and 5 by immunohistochemistry. SLN was the only metastasis lymph nodes in 14 out of 23 cases. One case was of false negative metastasis by SLN. The sensitivity and accuracy of SLNB were 96% (23/24) and 98% (56/57), respectively. The specificity was 100% (33/33) , the false negative rate was 4. 3% (1/23) with the negative predictive value being 97% (36/37). The positive predictive value was 100% (24/24). Internal mammary sentinel lymph node lymphoscintigraphy were positive in 11 cases but all the cases were negative in metastases by pathologic examination. Conclusion The combination of isotope imaging agent and patent blue is suitable for primary breast carcinoma after neoadjuvant chemotherapy. Internal mammary sentinel lymph node biopsy is less clinically important.